ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ASP5541

A development code.

Its studies are mostly in Prostatic Neoplasms, led by Astellas Pharma.

Furthest: phase 2, since May 27, 20252 company-led studies, 2 open or runningNext primary completion: Oct 31, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma22 open or runningphase 2since May 27, 2025May 27, 2025Oct 31, 2028phase 1 · NCT07339267

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 27, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07005154 · 218 planned · United States, China, France and more
  2. Jan 5, 2026Phase 1 study in Prostatic NeoplasmsNCT07339267 · 12 planned · China

Ahead

  1. Oct 31, 2028Primary completion: phase 1 study in Prostatic NeoplasmsNCT07339267
  2. May 31, 2032Primary completion: phase 2 study in Prostatic NeoplasmsNCT07005154

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07339267Prostatic Neoplasms · China1RecruitingOct 31, 202812
NCT07005154Prostatic Neoplasms · United States, China, France and more2RecruitingMay 31, 2032218

How it is read

Names in the registry

  • “ASP5541”, 2 entries

Codes read as this program: ASP5541.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.